Sanja Vrbek (Avtor), Irena Mlinarič-Raščan (Avtor), Žiga Jakopin (Avtor)

Povzetek

In the last decade, cancer immunotherapy has emerged as an effective alternative to traditional therapies such as chemotherapy and radiation. In contrast to the latter, cancer immunotherapy has the potential to distinguish between cancer and healthy cells, and thus to avoid severe and intolerable side%effects, since the cancer cells are effectively eliminated by stimulated immune cells. The cytosolic nucleotide%binding oligomerization domains 1 and 2 receptors (NOD1 and NOD2) are important components of the innate immune system and constitute interesting targets in terms of strengthening the immune response against cancer cells. Many NOD ligands have been synthesized, in particular NOD2 agonists that exhibit favorable immunostimulatory and anticancer activity. Among them, mifamurtide has already been approved in Europe by the European Medicine Agency for treating patients with osteosarcoma in combination with chemotherapy after complete surgical removal of the primary tumor. This review is focused on NOD receptors as promising targets in cancer immunotherapy as well as summarizing current knowledge of the various NOD ligands exhibiting antitumor and even antimetastatic activity in vitro and in vivo.

Ključne besede

ligandi;imunoterapevtiki;NOD1 agonisti;NOD1 antagonisti;NOD2 agonisti;NOD2 antagonisti;adjuvants;cancer immunotherapy;immunotherapeutics;NOD1agonists;NOD1 antagonists;NOD2 agonists;NOD2 antagonists;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.02 - Pregledni znanstveni članek
Organizacija: UL FFA - Fakulteta za farmacijo
Založnik: Wiley
UDK: 615.4:54
COBISS: 4641905 Povezava se bo odprla v novem oknu
ISSN: 1098-1128
Št. ogledov: 319
Št. prenosov: 145
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarni jezik: Slovenski jezik
Sekundarne ključne besede: Farmacevtska kemija;Imunoterapija;
Vrsta dela (COBISS): Članek v reviji
Konec prepovedi (OpenAIRE): 2019-12-13
Strani: str. 1447-1484
Letnik: ǂVol. ǂ39
Zvezek: ǂiss. ǂ5
Čas izdaje: 2019
DOI: 10.1002/med.21557
ID: 12639655